Clinical Trial Update: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating eribulin mesylate with PEGPH20 versus eribulin alone in HER2-negative, high-hyaluronan metastatic breast cancer was terminated; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• PEGPH20 (pegylated recombinant human hyaluronidase) (PEGPH20)

Snippet

Sponsor: Eisai Inc. | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-07-13